U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
Efficacy and safety of pipeline multiple sclerosis assets viewed as increasingly important characteristics, according to Spherix Global Insights. [Exton PA, December 13, 2023] — Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS). These BTKis, administered orally, possess the advantage of easy dosing while leveraging their […]
Survey finds neurologists seek to minimize side effects of treatment in Parkinson’s
Fewer than half of those dealing with Parkinson’s disease in the United States are able to gain clinical control of symptoms without experiencing side effects, according to results of a new study. Spherix Global engaged its initial Insights’ Market Dynamix to canvas more than 100 neurologists, employing a combination of quantitative survey and qualitative interview […]
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson’s Disease, According to Spherix Global Insights
Gene therapies and LRRK2 inhibition are at the forefront of prescribers’ interest, highlighting the need for a truly disease modifying therapy. [Exton PA, November 7, 2023] — Parkinson’s disease (PD) is the second-most prevalent neurodegenerative disorder following Alzheimer’s disease, affecting an estimated one million individuals in the United States1. With a significant absence of a […]
Pfizer and AbbVie oral migraine drugs earn top spots with physicians, survey finds
Oral drugs have raced to the front of the pack in the crowded migraine therapy space and appear to be staying put with physicians. Primary care physicians in particular are prescribing Pfizer’s Nurtec and AbbVie’s Ubrelvy and Qulipta, according to Spherix Global Insights’ latest quarterly survey of migraine drug prescribers. Primary docs reported more than […]
Another Medicine to Stop Migraine in its Tracks – Zavzpret™ is Now Available, but Where will Neurologists use it?
Will Pfizer’s marketing power help Zavzpret™ rapidly gain share in the crowded migraine market? Exton, PA., August 17, 2023 –In February 2023, Pfizer published their positive Phase 3 clinical trial results for zavegepant (new brand name, Zavzpret™). At the time, neurologists surveyed in a Spherix Global Insights study were “cautiously optimistic” that the first-ever, CGRP receptor […]
What’s on Your Must-Read List? If You Work in Pharma, Add Spherix Global Insights’ Generalized Myasthenia Gravis Patient Chart Audit to that List
US neurologists in Spherix’s in-house physician network complete a patient chart audit of over 600 patients with gMG. Exton, PA, August 10, 2023 – In one of the largest patient-focused studies ever conducted in gMG, Spherix’s RealWorld Dynamix™: Treatment Patterns in generalized Myasthenia Gravis not only illuminates critical aspects of patients’ presentation, diagnosis, and management […]
How High Is the Bar for Future ALS Treatments? Although Neurologists Express Frustration with Current Treatments, They Are Quick to Adopt Therapies that Promise to Delay ALS Progression
According to Spherix Global Insights first market landscape study on Amyotrophic Lateral Sclerosis (ALS), general neurologists lack awareness of therapies in development for ALS. EXTON, Pa., August 2, 2023 – A quiet but significant advance was made during the last year: not one, but two medicines were FDA approved to delay disease progression in the […]
Breaking Into a Saturated Relapsing Remitting Multiple Sclerosis Market: Where Should Developers Focus?
According to Spherix Global Insights, U.S. neurologists are largely satisfied with current treatment choices in the RMS market, but opportunities remain. Exton, PA, August 1, 2023 – Despite outward appearances of being a stagnant market, the relapsing remitting multiple sclerosis market continues to offer drug developers opportunities to break in – if their new assets offer […]
At Eighteen Months Post-Launch, Impel’s Trudhesa Has Struggled to Keep Up with Pfizer’s Nurtec ODT and AbbVie’s Ubrelvy, According to Spherix Global Insights
Use of Trudhesa as an acute migraine treatment is on par with the more-established Reyvow, though future projections have it exceeding the Eli Lilly offering. Exton, PA., April 14, 2023 – Spherix Global Insights recently released data from their Launch Dynamix™: Trudhesa in Acute Treatment of Migraine (US) deep dive study tracking the launch of […]
Imaging required to monitor effects of new Alzheimer’s drug could inhibit its uptake
Although providers are optimistic about the potential of a new treatment for Alzheimer’s, some are concerned that the burden of monitoring the drug’s effect on patients could limit its uptake. In January 2023, Eisai/Biogen’s Leqembi—a drug shown to reduce clinical decline by up to 27% in patients with Alzheimer’s—was given accelerated approval by the U.S. Food and Drug […]
